Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06287944
Title field or adapter rule
{'original_value': 'Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At
2026-10-31T23:27:28.985333+00:00
Published At
2026-10-30T00:00:00+00:00
Record Updated At
2026-10-30
Source Retrieved At
2026-10-31T22:18:11.341859+00:00
Timestamp Basis
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Myelodysplastic Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId
"NCT06287944"
protocolSection.identificationModule.officialTitle
"Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct
null

Study condition terms

  • Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Given IV', 'name': 'Actinium Ac 225-DOTA-Daratumumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Undergo blood sample collection', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Undergo bone marrow biopsy and aspiration', 'name': 'Bone Marrow Aspiration', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Undergo bone marrow biopsy and aspiration', 'name': 'Bone Marrow Biopsy', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Undergo CT', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Given IV', 'name': 'Daratumumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Undergo echocardiography', 'name': 'Echocardiography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Given IV', 'name': 'Fludarabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Undergo SCT', 'name': 'Hematopoietic Cell Transplantation', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Given IV', 'name': 'Indium In 111-DOTA-Daratumumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Given IV', 'name': 'Melphalan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Undergo MUGA', 'name': 'Multigated Acquisition Scan', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Undergo nuclear scan', 'name': 'Radionuclide Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Undergo SPECT scan', 'name': 'Single Photon Emission Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Given sirolimus', 'name': 'Sirolimus', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Given tacrolimus', 'name': 'Tacrolimus', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment ( Actinium Ac 225-DOTA-Daratumumab)'], 'description': 'Undergo TMLI', 'name': 'Total Marrow and Lymphoid Irradiation', 'type': 'RADIATION'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

  • Fludarabine (protocolSection.armsInterventionsModule.interventions[].name)
  • Melphalan (protocolSection.armsInterventionsModule.interventions[].name)
  • Sirolimus (protocolSection.armsInterventionsModule.interventions[].name)
  • Tacrolimus (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.